chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the immunoglobulin shot in my right butt cheek, then received a first vaccine a day or two prior to the 2nd round. Then I received the 2nd round of RABAVERT around 8/10/2014. Hours after receiving the 2nd shot, my vision went red, my conscious state descended into a hazy dream state, my arms and legs began tinging and burning (pins and needles sensation) and I had perceived sensory loss in my appendages. My blood pressure was dangerously high and I could hardly walk/move my arms above my head or feel anything other than nerve pain for about 6 months. It was way too difficult to do many tasks that were once normal for me. EMG, MRI, CAT scans all came back negative for MS, ALS, tumors, etc. Peripheral Neuropathy was the diagnosis.
This report describes the occurrence of mercury poisoning in an 18 month old male who was vaccinated with hepatitis B vaccine recombinant for prophylaxis. This report was received as part of litigation proceedings and has not been verified by a physician or other health care professional. The subject was allegedly born a perfectly normal, healthy boy whose Apgar scores at birth were well within the normal range. Developmentally, neurologically and socially, he achieved every developmental milestone anticipated of all normally developing children until the age of 18 months. The subject received injections of Engerix B on 11/19/98 and 2/10/00. He also received injections of diphtheria and tetanus toxoids and pertussis vaccine and Haemophilus influenzae type B conjugate vaccine. The subject's attorney alleged that the subject suffered devastating injuries through mercury toxicity and associated complications and sequelae and the aggravation of other conditions directly through exposure, via an IM injection of mercury. The subject's attorney further alleged that at approximately 18 months of age, the subject was neurologically devastated by the accumulation of Mercury in his body, having been exposed via IM vaccinations, and suddenly regressed developmentally, losing milestones of neurological development previously achieved, specifically including, but not limited to becoming withdrawn, unable to speak, unresponsive to his environment, engaging in repetitive behavior and the loss of language skills, motor skills and affect. Treatment and outcomes of these events were not specified. The mercury poisoning and developmental regression in this report are considered medically serious.
When patient got up this AM she noticed her (R) arm was sore & swollen. As the day went on it gradually worsened. Patient was advised to take BENADRYL and TYLENOL or Ibuprofen. Swelling had not gone past elbow.
extreme fatigue; chills; aches; Fever; This is a spontaneous report from a contactable consumer. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration on 24Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient experienced extreme fatigue, chills, aches, fever on an unspecified date. Outcome of events fatigue, chills, aches, was not recovered, fever was recovered.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Tightness in chest; dizziness; chills; headache; warm red injection site; warm red injection site; This is a spontaneous report from a contactable consumer (patient herself). A 79-year-old non-pregnant female patent received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EL9267), via an unspecified route of administration in left arm at the age of 79-years (non-pregnant at the time of vaccination), on 17Feb2021 at 01:30 AM at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously took first dose of bnt162b2 (Lot number: EL8982), via an unspecified route of administration in left arm at the age of 79-years on 27Jan2021 at 01:30 AM at a single dose for COVID-19 immunisation. The patient received any other vaccines within 4 weeks prior to the COVID vaccine was reported as no. The patient was not diagnosed with COVID-19 prior to vaccination. The patient experienced tightness in chest, dizziness, chills, headache and warm red injection site on 17Feb2021. The seriousness of the events was reported as no. The patient did not receive any treatment for the events. The outcome of the events was recovering. It was also reported that since the vaccination, the patient had not been tested for COVID-19.
Information has been received from a physician concerning a 24 year old female who on 22-JAN-2010 was vaccinated with the first dose of GARDASIL, IM (lot# 1702X). On 22-MAR-2010, the patient was vaccinated with the second dose of GARDASIL, IM. It was reported that on an unspecified date, the patient experienced "stomach issues" such as abdominal pain with uncertain causation. An abdominal ultrasound of the "abdominal and bladder area" was performed (no results were provided). Additional information has been requested.
My 4th anthrax booster was given on 17 Oct 2007 upon my return from one country to another. On 2 Nov 2007, 16 days later, I experienced a cardiac event (SVT). The only thing now in my system when asked by doctors what I had different, was the booster. I have no history of heart ailments. The SVT was a one time event. 9/24/08-records received-11/2/07 C/O dizziness, palpitations, chest tightness. Diagnosed with SVT.  MI ruled out. Office visit 2/27/08-C/O coughing, congestion and runny nose, post nasal drip and sore throat times 1 week.
This spontaneous report as received from a consumer refers to her cousin, an approximately 3 years old male patient. On an unknown date, in early 1990's the patient was vaccinated with M-M-R II, (therapy type HSA, dose and Lot# were not reported). On an unknown date, immediately after vaccination, the patient experienced general grand mal seizures that continued to worsen throughout a one year period. On an unknown date, when the patient was having up to 40 seizures a day, he was admitted to a hospital. On an unknown date, reported as one year after vaccination with M-M-R II the patient died. The cause of death was reported as seizure. Relatedness between grand mal seizure and M-M-R II was not reported. Upon internal review general grand mal seizures were considered to be medically significant. Additional information has been requested.
Routine catch up immunization for school PE. After vaccine administration 1 hour, he developed chest pain, coughing, chest tightness and face rash. Epiniephrine x1 given sent to ER for further TX.
Body aches and fever for 36+ hours. Onset of side effects took almost 11 hours post vaccine.
This spontaneous report as received from a nurse practitioner refers to an unspecified number of patients of unknown age and gender. In October 2014 (exact date unspecified, reported as between 08-OCT-2014 and 22-OCT-2041) those patients were intramuscularly vaccinated with an improperly stored at 31F for 10 hours GARDASIL once (0.5 ml, lot number was not reported). No adverse effects reported. This is one of several reports from the same reporter. Additional information has been requested.
Mild fever,  hot sweats, body ache, nausea, sore arm, headache, moderate fatigue
Presented with SOB/ productive cough/pleurisy; fully vaccinated; dx COVID 4 days PTA; treated with azithromycin & doxcycline PTA; dx Covid PNA. Treated with remdesivir, O2, steroids, plasma, Vit C, Vit D, zinc, convalescent plasma, doxcycline, antibiotics. D/C Home with HHC.
This spontaneous report as received from a medical assistant refers to a patient of unknown age or gender. No information was provided regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies. On an unspecified date between mid-June and 14-SEP-2017, the patient was vaccinated with improperly stored dose of ROTATEQ, orally (dose number, exact dose were not reported; lot # M018958 with the expiration date of 03-MAR-2018), for prophylaxis. No adverse effects were reported. The dose of ROTATEQ underwent a temperature excursion of 34.57 degrees Fahrenheit for the time frame of 17 minutes. Digital data logger was used to capture the temperature excursion. There were no previous temperature excursions reported. This is one of two reports received from the same reporter. Sender's Comments: US-009507513-1709USA009961.
Granuloma annulare; I just had rash; This is a spontaneous report from a contactable consumer (patient). An unspecified age female patient received an unspecified dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date (Expiration date: Unknown) as single dose for COVID-19 immunization. Medication history and concomitant medication were not reported. On an unspecified date, the patient experienced granuloma annulare and rash. Caller was asked if there have been any reports with the Pfizer-BioNTech COVID-19 Vaccine of a rash called Granuloma annulare. The outcome of events was unknown.  Information on the lot/batch number has been requested.
sickness; Brain operation; This spontaneous case was reported by a consumer and describes the occurrence of BRAIN OPERATION (Brain operation) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No other medical history was reported. .    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In July 2021, the patient experienced BRAIN OPERATION (Brain operation) (seriousness criterion medically significant). On an unknown date, the patient experienced ILLNESS (sickness). At the time of the report, BRAIN OPERATION (Brain operation) and ILLNESS (sickness) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   On an unknown date, the patient experienced sick. In July 2021, the patient experienced brain surgery. Moderna vaccine was also considered suspect.  She took Covid shot and got sick after taking Humira.  It was unknown if patient was enrolled in a COVID-19 vaccine trial.  No treatment medication was provided.  This Case was Identified as part of retrospective email clean-up activity which included identification and booking-in of historical emails.   Company comment: This is a spontaneous case reported by a consumer. A 38-year-old female patient, in treatment with Adalimumab for Crohn's disease, received a dose of mRNA-1273 vaccine and experienced medically significant event of brain operation and non serious event of illness. Vaccination date was not provided; hence, latency cannot be assessed. It was reported that, in Jul 2021, the patient had brain surgery. She received Covid vaccine and got sick after taking Humira. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Concurrent condition Crohn's disease and concomitant product Humira could be contributory factors for event illness. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case reported by a consumer. A 38-year-old female patient, in treatment with Adalimumab for Crohn's disease, received a dose of mRNA-1273 vaccine and experienced medically significant event of brain operation. Vaccination date was not provided; hence, latency cannot be assessed. It was reported that, in Jul 2021, the patient had brain surgery. She received Covid vaccine and got sick after taking Humira. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Concurrent condition Crohn's disease and concomitant product Humira could be contributory factors for event illness. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Covid; Covid; This is a solicited report received from contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 61-year-old male patient received BNT162b2 (BNT162B2), on 30Sep2021 as dose 1, single (Batch/Lot number: unknown), on 28Dec2021 as dose 2, single (Batch/Lot number: unknown) and on 23Jul2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 61 years, all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Lot number: 1160186), subcutaneous for crohn's disease. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Sep2022, outcome "recovering" and all described as "Covid". The action taken for adalimumab was unknown.  The reporter's causality for the event of Covid with Adalimumab Solution for Injection was No Reasonable Possibility. The reporter's causality for the event of Covid with Pfizer BioNTech COVID-19 vaccine (Tozinameran) was Reasonable Possibility.   opinion was that the causality for the event of Covid with Adalimumab Solution for Injection was Not Provided. Opinion was that the causality for the event of Covid with Pfizer BioNTech COVID-19 vaccine (Tozinameran) was Not Provided.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information provided in the narrative, a causal association between the events and the suspect drug cannot be completely excluded.
armpit is really badly swollen; body aches; collar bone is swollen; broken out in a fever; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (armpit is really badly swollen), PAIN (body aches), SWELLING (collar bone is swollen) and PYREXIA (broken out in a fever) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On 19-Apr-2021, the patient experienced SWELLING (armpit is really badly swollen), PAIN (body aches), SWELLING (collar bone is swollen) and PYREXIA (broken out in a fever). At the time of the report, SWELLING (armpit is really badly swollen), PAIN (body aches), SWELLING (collar bone is swollen) and PYREXIA (broken out in a fever) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator No treatment medications provided by the reporter.
No additional AE; Product was adminisered to patient after temperature excursion; This spontaneous report was received from a physician referring to a approximately 4-year-old patient. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not provided.  On an unknown date in January 2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rHA) (PROQUAD) once (lot number U022729, expiration date 16-JAN-2023 ; dose, dose number, vaccination scheme, and anatomical location of vaccination were not reported) for prophylaxis.         On 28-JAN-2022, the measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rHA) (PROQUAD) was administered to patient after temperature excursions. (product storage error). The vaccine was stored for the time frame of 25 minutes in the temperature of 7.4 degree Fahrenheit (F), 20 minutes in the temperature of 6.4 degrees F,15 minutes in the temperature of 5.9 degrees F.  The previous temperature excursion of the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) was stored at 31.3 degrees F for 28 minutes (min), from 6 degrees F to 14 degrees F (exact temperature was not provided) for 1 hour 15 min and 11 degrees F for 4 hours 6 min. No product quality complaint (PQC) and no additional adverse event (AEs) (no adverse event) was reported.  This is patient (report) number seven, out of seven total.
Patient with newly identified leptomeningeal tumor on imaging (imaging ordered prior to vaccine administration based on clinical exam during office visit).  Admitted for pain control , acute cancer therapy, urinary retention. Unclear if patients symptoms acutely worsened post vaccination.
Diarrhea; Very achy; Extremely nauseated; Chills; Severe headache; This is spontaneous report from a contactable consumer, the patient. A 58-years-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown), via unspecified route of administration in the left arm on 15Mar2021 at 11:15 am (at the age of 58-years-old), as single dose for COVID-19 immunisation. Medical history included severe asthma and patient had no allergies to medications, food, or other products. Concomitant therapies included Xolair received on 11Mar2021, Lexapro, Trelegy, levothyroxine (MANUFACTURER UNKNOWN), lisinopril (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16Mar2021, the patient experienced very achy, extremely nauseated, had diarrhea, severe headache and chills. The patient did not receive any treatment for the events. The clinical outcome of the events very achy, extremely nauseated, diarrhea, severe headache and chills was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Fatigue, had to miss work; muscle weakness, had to miss work; body aches, had to miss work; This case was reported by a consumer via call center representative and described the occurrence of fatigue in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included allergy to antibiotic (allergic to Levaquin, Biaxin and Bactrim), allergic reaction to analgesics (allergic to codeine) and sulfonamide allergy (allergic to Sulfa).   On 1st November 2021, the patient received Shingrix. In November 2021, less than a week after receiving Shingrix, the patient experienced fatigue, muscle weakness and general body pain. On an unknown date, the outcome of the fatigue, muscle weakness and general body pain were unknown.   It was unknown if the reporter considered the fatigue, muscle weakness and general body pain to be related to Shingrix.  Additional details provided were as follows: Age at vaccination was not reported. The patient received a dose of Shingrix on Monday due to which he/she had missed work yesterday and at the day of reporting and experienced body aches, muscle weakness and fatigue. The patient was allergic to Sulfa, Levaquin, Biaxin, Bactrim and Codeine. Follow-up would not be possible as no contact details available.
Headache, Fever, cold, chills, fever 99.8, lower back pain,achy knee joint Narrative:
Exhibited fussiness at bedtime, was found deceased after 7am next morning. Med examiner report states cause undetermined and lists focal congestion and hemorrhage of liver, lungs, and heart. No additional terms added from autopsy report rec'd 01/18/2006/sr
Pt recvd vax & 4 days p/vax had aching in muscles, chills, dizziness & lightheadedness; pt awoke in noc w/sore throat, fever, earache; pt had h/a, tiredness, pain in legs & sping & sweaty palms;
Pt vaccinated MMR experienced nervous system damage which included encephalopathy, which resulted in internal, neurological, orthopeidc, psychological, & psychiatric injuries.
Around 5pm on date of vaccination, pt. reported a vibration sensation in her left anterior wrist area. The vibration was intermittent, lasting about 3 seconds per episode, about 4 times a day, for 2-3 days, and then resolved and has not occurred since then.
Patient reports being sick 2 days after receiving vaccinations: symptoms included:  headaches, congestion, chest pain, difficulty sleeping, foggy brain, decreased appetite. Patient states that the symptoms have continued since receiving the vaccines. She was seen at the medical center on 14Jan2020 for the above symptoms. Patient was prescribed medications, chest x-ray completed which was unremarkable, and was instructed to follow up in one week if symptoms do not improve with medications.
This spontaneous report was received from a 39-year-old female patient with no pertinent medical history. Current conditions included allergy to dexamethasone, hydrocodone and PERCOCET.  On 31-JAN-2013 the patient was vaccinated with, 0.5 milliliter (ml) PNEUMOVAX23 (lot# and expiration date not reported) intramuscularly in the right arm. Concomitant medications included vitamins and amitriptyline hydrochloride. Within a few hours of receiving PNEUMOVAX23 the injection site became red and hot. A large "knot" developed at the injection site. Patient experienced severe pain at the injection site and the lymph nodes in the armpit of her right arm swelled. She had muscle aches, joint pain, nausea, headache and a low grade fever. Patient visited an unspecified urgent care facility on 02-FEB-2013. She was treated and advised to take an unspecified anti inflammatory. On 04-FEB-2013 the swelling at the injection had dissipated (resolved) however patient was still feverish and there was redness and heat at the injection site. Patient would be visiting her unspecified primary care physician sometime this week to follow-up. Outcome of the rest of the reported events were unknown. No further information available. Additional information has been requested.